Nasus Pharma Ltd. (NSRX)
| Market Cap | 44.22M -28.3% |
| Revenue (ttm) | n/a |
| Net Income | -10.55M |
| EPS | -1.07 |
| Shares Out | 11.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,522 |
| Open | 3.855 |
| Previous Close | 3.840 |
| Day's Range | 3.757 - 3.910 |
| 52-Week Range | 1.980 - 9.500 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 19.67 (+421.06%) |
| Earnings Date | Aug 17, 2026 |
About NSRX
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for NSRX stock is "Buy." The 12-month stock price target is $19.67, which is an increase of 421.06% from the latest price.
News
Nasus Pharma announces first patient enrolled, dosed in Phase 1 trial of NS003
Nasus Pharma (NSRX) announced that the first patient has been enrolled and dosed in the Company’s Phase 1 pharmacokinetic trial of NS003, its proprietary intranasal powder formulation of ondansetron b...
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026 Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-admin...
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
TEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of in...
Nasus Pharma files $50M ordinary shares offering
16:52 EDT Nasus Pharma (NSRX) files $50M ordinary shares offering
Nasus Pharma Registration statement: Registration filing
Nasus Pharma filed a registration statement on September 1, 2026, providing details about a securities offering with the SEC.
Nasus Pharma Announces Transition of Chief Financial Officer
TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the developme...
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
Appointed Pharma Industry Veteran Brendan O'Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE NE...
Nasus Pharma appoints Brendan O’Grady as CEO
Nasus Pharma (NSRX) announced the appointment of pharma industry veteran Brendan O’Grady as its CEO. O’Grady will lead the company’s next phase of growth, with an initial focus on unlocking…
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of inn...
Nasus Pharma Transcript: Life Sciences Virtual Investor Forum
A proprietary powder nasal drug delivery platform is advancing a lead epinephrine product for anaphylaxis, showing faster and higher absorption than EpiPen and entering phase III in late 2024. The company is well-funded through mid-2027, expanding its pipeline to other acute indications, and is receiving strong support from clinical experts.
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
TEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...
Nasus Pharma Transcript: KOL event
The event highlighted the growing need for needle-free epinephrine, with strong clinical data showing rapid onset and high patient preference for intranasal delivery. KOLs emphasized the product's potential to expand the market and improve adherence, with a pivotal phase III study planned.
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study; Program to Advance to First-in-Human PK Study ...
Nasus Pharma Slides: Company presentation
Nasus Pharma has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...
Nasus Pharma to Participate in Upcoming Investor Conferences
TEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative in...
Nasus Pharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators
A proprietary powder-based intranasal platform is advancing multiple acute care therapies, led by a needle-free epinephrine product that outperforms EpiPen in speed and absorption. Phase III trials begin Q4, with NDA submission planned for mid-2027, and several pipeline products are entering the clinic this year.
Nasus Pharma price target lowered to $18 from $19 at Citizens
Citizens lowered the firm’s price target on Nasus Pharma (NSRX) to $18 from $19 and keeps an Outperform rating on the shares. Following the quarterly results, the firm believes NS002…
Nasus Pharma Earnings release: Q4 2025
Nasus Pharma released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
Nasus Pharma Annual report: Q4 2025
Nasus Pharma has published its Q4 2025 annual report on March 25, 2026.
Nasus Pharma Earnings release: Q4 2025
Nasus Pharma released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
Nasus Pharma advances NS002 to pivotal study following Phase 2 results
Nasus Pharma (NSRX) provided a business update highlighting recent Phase 2 results for NS002, its intranasal powder epinephrine product candidate for anaphylaxis. The company reported topline results ...
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study ...
BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript
In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for th...